Stock of the Day

September 24, 2020

Charles River Laboratories International (CRL)

$300.35
-$5.89 (-1.9%)
Market Cap: $14.62B

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Today's Trend

Charles River Laboratories International, Inc. (NYSE: CRL) shares have decreased in the latest session despite a largely favorable flow of analyst commentary and business updates. The pullback may reflect profit-taking after the stock’s strong rally—shares are up 75.8% over the past year—rather than a major deterioration in the company’s outlook.

  • Analysts raised earnings forecasts. Zacks Research increased its FY2026 EPS estimate to $11.17 from $11.15, FY2027 to $12.54 from $12.49, and FY2028 to $13.92 from $13.82. It also made modest upward revisions to several quarterly estimates and maintained a “Strong-Buy” rating. Zacks Research earnings forecast
  • UBS upgraded CRL to Strong Buy, providing additional institutional support after the company’s substantial 12-month advance. UBS upgrade
  • Operational momentum remains a key bullish theme. Recent coverage points to improving Research Models and Services trends, expanding AI-enabled testing, healthy cash flow, and the ability to fund share buybacks and investment. Charles River rally analysis
  • Charles River and Autolomous launched Apollo Orchestrate, a digital laboratory-execution solution integrated within Charles River’s Apollo platform. The initiative could strengthen the company’s technology offering and improve laboratory efficiency. Apollo Orchestrate launch
  • A Zacks comparison examines whether CRL or Progyny offers the more attractive value opportunity. The article may influence valuation-focused investors, but the headline does not disclose a definitive preference. PGNY versus CRL value analysis
  • Valuation and recent gains may be limiting near-term upside. With CRL near its 12-month high after a powerful rally, investors may be taking profits while awaiting further earnings confirmation. The company’s latest reported revenue declined 2.7% year over year, adding a reason for caution despite earnings beating estimates.
← Previous Stock of the DayNext Stock of the Day →

Recent News